Attovia Therapeutics IPO: revenue, losses and offering terms from its S-1
Attovia Therapeutics priced its IPO at $17 a share on 5 Aug 2026 and raised $289 million. Its shares trade on Nasdaq as ATTO. Revenue was $1.4 million in 2025, with a net loss of $60.6 million.
Headlines
- Revenue, 2025
- $1M
- Net loss, 2025
- $61M
- IPO price
- $17
- $289M raised
Attovia Therapeutics IPO terms
From the final prospectus (424B4).
- Exchange
- Nasdaq Global Market
- Ticker
- ATTO
- IPO price
- $17
- Shares offered
- 17,000,000
- Raised
- $289M
- Registered
- $332M, the amount the filing fee is paid on
- Underwriters
- Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets and LifeSci Capital
- First filed
- 14 Jul 2026
Attovia Therapeutics revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2025 | $1M | -$67M | -$61M |
| First quarter of 2026 | - | -$20M | -$19M |
Attovia Therapeutics share structure and company facts
- Employees
- 44
- Headquarters
- San Carlos, California
Attovia Therapeutics shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $17
- Priced 5 Aug 2026
- First close
- $21.90
- +29% on the IPO price
- Latest close
- $13.88
- -18% on the IPO price
Attovia Therapeutics' IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Attovia Therapeutics' newest prospectus (424B4 filed 5 Aug 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.